LoadingLoadingLoadingThe quick read
Latest quote·Oct 15
Net selling: insiders sold $16M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net buying of $35K to $99K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNet selling: insiders sold $16M and bought $0 of LLY stock on the open market in the 90 days to Oct 16, 2026, according to SEC Form 4 filings. $16M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Jonsson, Patrik (EVP & President, LLY Int'l), who sold $7.6M. The latest filing was on Aug 18, 2026.
Rep. Michael Rulli (R) sold $1K to $15K on Jul 1, 2026, disclosed 37 days later. Rep. Gilbert Cisneros (D) bought $50K to $100K on Jun 10, 2026, disclosed 22 days later. In total, 2 members disclosed 2 LLY trades with trade dates in the last 180 days, filed a median 30 days after trading.
This summary uses filings available on Oct 16, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
8 funds hold a position, insiders have been net selling, and 1 fin-fluencer is discussing it.
Buys/Adds (2)
Citadel
$911.7M
added
Susquehanna
$282.2M
added
Sells/Trims (1)
Qube Research
$242.1M
trimmed
Buys (1)
Sells (2)
Trader E15Short
$61K
position
Trader 295Long
$41K
position
Trader 5B7Short
$21K
position
Trader 447Short
$8K
position
Trader 977Long
$2K
position
Last report
Aug 5, 2026
Financial period
Q2 2026
Earnings per share
$6.01 expected
Revenue
No reported revenue on record
FY2026 guidance
$85.00B to $87.00B
No comparable estimate
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 5, 2026 | $8.38 / $6.01Alpha Vantage | +39.43% beat | Unavailable | Unavailable |
| Mar 31, 2026 | Apr 30, 2026 | $8.55 / $6.79Alpha Vantage | +25.92% beat | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 4, 2026 | $7.54 / $7.17Alpha Vantage | +5.16% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Oct 30, 2025 | $7.02 / $5.89Alpha Vantage | +19.19% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 7, 2025 | $6.31 / $5.61Alpha Vantage | +12.48% beat | Unavailable | Unavailable |
| Mar 31, 2025 | May 1, 2025 | $3.34 / $3.46Alpha Vantage | -3.47% miss | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 6, 2025 | $5.32 / $5.07Alpha Vantage | +5.00% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Oct 30, 2024 | $1.18 / $1.47Alpha Vantage | -19.73% miss | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Estimates as of Oct 16, 2026
EPS expected
$4.65 to $11.30
Revenue expected
15 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $17.60B | $19.29B | $19.80B | $22.97B |
| Cost of what it sold | $3.01B | $3.37B | $3.58B | $3.27B |
| Gross profit | $14.59B | $15.92B | $16.22B | $19.71B |
| What it spent | ||||
| Research and development | $3.47B | $3.80B | $3.51B | $3.82B |
| Sales and admin | $2.74B | $3.34B | $2.93B | $3.43B |
| Other operating costs | — | -$212.1M | — | — |
| Total operating expenses | $6.21B | $6.93B | $6.44B | $7.25B |
| What was left | ||||
| Operating profit | $8.39B | $8.99B | $9.78B | $12.46B |
| Interest on debt | $179.6M | $123.0M | $332.0M | $345.0M |
| Profit before tax | $7.23B | $8.27B | $8.85B | $9.25B |
| Tax | $1.65B | $1.63B | $1.45B | $2.15B |
| Net profit | $5.58B | $6.64B | $7.40B | $7.09B |
| EBITDA | $7.88B | $12.14B | $10.29B | $12.99B |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
CVS Health Corporation $CVS Stock Sold by Curated Wealth Partners LLC
NeutralOct 16Eli Lilly reports Omvoh data: Eli Lilly stock trades 1.46 percent lower
NeutralOct 16A 305,000-share sale is proposed by Eli Lilly (LLY) shareholder Lilly Endowment.
NeutralOct 15Gilead Sciences Inc Stock (GILD) Moved Up by 3.67% on Oct 15: Key Drivers Unveiled
BullishOct 15AstraZeneca PLC Stock (AZN) Moved Up by 3.55% on Oct 15: What Signal Does It Send?
Leans bullishOct 15Pfizer Stock Hits 52-Week High: What's Going On?
Leans bullishOct 15Novartis AG Stock (NVS) Moved Up by 3.00% on Oct 15: Drivers Behind the Movement
Leans bullishOct 15Micron Technology is lagging Eli Lilly, Berkshire Hathaway and maybe soon Walmart in market cap
Leans bullishOct 1531 macro signals shaping LLY right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results